eligibility_summary
Inclusion: children 5–17 with newly diagnosed AAGN, renal biopsy, regular follow‑up, meet EMA 2007/CHCC 2012 ANCA criteria (MPA, GPA, EGPA) and have ANCA vasculitis plus hematuria, proteinuria, or renal insufficiency per defined thresholds. Exclusion: dialysis >1 month or glomerulosclerosis ≥75%, severe infection or malignancy, other kidney diseases, or refusal to participate.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05969522 tests risk‑stratified induction for pediatric ANCA‑associated glomerulonephritis. Drugs/interventions: 1) Glucocorticoids (IV methylprednisolone, oral prednisone): systemic corticosteroids that bind the glucocorticoid receptor, suppress NF‑κB/AP‑1–mediated transcription, reduce cytokines, leukocyte trafficking, and neutrophil activation. 2) Rituximab: anti‑CD20 chimeric monoclonal antibody that depletes B cells, lowering ANCA autoantibody production and antigen presentation. 3) Cyclophosphamide: alkylating agent causing DNA crosslinking and apoptosis of proliferating lymphocytes, broadly immunosuppressive. Regimens: high‑risk = steroids + rituximab + cyclophosphamide, low/medium‑risk = steroids + rituximab. Targets: CD20+ B cells (ANCA sources), humoral autoimmunity, neutrophil‑driven small‑vessel inflammation, and pro‑inflammatory cytokine pathways.